Lacouture ME, Reilly LM, Gerami P et al.
Northwestern University’s Feinberg School of Medicine, Chicago, IL, USA.
Ann Oncol 2008;19:1955–61.Editor’s note:
Hand–foot skin reaction (HFSR) is a clinically important side effect associated with use of the agents sorafenib and sunitinib, affecting 20–30% of treated patients (Lancet Oncol
2005;6:491–500, N Engl J Med
2007;356:125–34, N Engl J Med
2007;356:115–24). HFSR can significantly impair the quality of life of patients receiving these drugs and may result in the need to reduce the dose or delay therapy, with important consequences for the treatment of renal cell carcinoma. In the present study, the clinico-pathological findings of HFSR were examined in patients treated with sorafenib or sunitinib who were referred to a single dermatological center in 2007 and then compared with previously reported findings of hand–foot syndrome (HFS) in patients treated with standard cytotoxic therapy.